Home » Glioma Treatment Market Overview, High Growth Opportunities, Segmentation, Trends By 2022-2031

Glioma Treatment Market Overview, High Growth Opportunities, Segmentation, Trends By 2022-2031

by jamesrosen85
  • The global glioma treatment market was valued at US$ 4.39 Bn in 2021
  • The global market is projected to grow at a CAGR of 5.7% from 2022 to 2031
  • The global glioma treatment market is anticipated to reach more than US$ 7.51 Bn by 2031

Analysts’ Viewpoint on Glioma Treatment Market Scenario

Surge in number of surgeries performed across the globe and major technological innovations in radiation therapy for glioma, molecular therapies, chemotherapy, and targeted therapies are driving the global glioma treatment market. Furthermore, notable growth potential in emerging countries such as India, South Korea, and Brazil is projected to boost the glioma treatment market during the forecast period. However, less survival rate and lack of awareness are estimated to hamper the global market in the near future. Nevertheless, increase in investments by public & private organizations and entry of various startups into the glioma treatment market are likely to lead to positive sentiment among patients toward effective treatment.

Global Glioma Treatment Market Introduction

Glioma is a condition that covers a broad category of brain and spinal cord tumors that affect the glial cells in the brain. Glioma can affect brain function and can be fatal depending on its location and severity of the tumor. Different types of gliomas are astrocytoma, brain stem gliomas, ependymomas, mixed gliomas (oligo-astrocytomas), oligodendrogliomas, and optic pathway gliomas. Common glioma symptoms include headache, nausea, vomiting, confusion, and decline in brain function. Various therapeutic options are available for the treatment of glioma. These include radiation therapy for glioma, chemotherapy, glioma targeted therapy, and surgery. Late stage clinical pipeline drugs can be effective treatment options for glioma.

Get a sample of the report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84872

Approval of late stage pipeline drug designation to certain molecules for the treatment of glioma is a major factor that is likely to drive the global glioma diagnosis and treatment market. For instance, on December 05, 2019, the U.S. FDA and European Medicines Agency granted orphan drug designation to Adastra Pharmaceuticals drug zotiraciclib, a multikinase inhibitor. This drug is being evaluated in two phase 1b clinical studies of patients with glioblastoma ‒ the most common glioma histology for the treatment of glioma. Rise in prevalence of brain cancer and increase in awareness regarding various types of gliomas are also fueling the global glioma treatment market. Moreover, strategic alliances for the development of glioma therapeutics products and increase in exposure of humans to radiation in the last few years, which leads to higher incidence of brain cancer, are some of the key factors propelling the global glioma therapy market.

COVID-19 Impact on Global Glioma Treatment Market

The outbreak of COVID-19 has had a negative effect on the global glioma treatment market. Governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Surgical neuro-oncology is a specialty that created a dilemma in continuing surgical care during the pandemic. Several ICU facilities, such as ventilators, personal protective equipment, and medical staff, were rerouted to COVID-19 cases, prompting the suspension of surgical neuro-oncology services during the pandemic. Instability in the provision of adequate medical care to critically-ill cancer patients was witnessed during the pandemic. Additionally, glioblastoma patients are vulnerable to the COVID-19 infection, which led to postponement of treatments and surgeries. Thus, there was a decrease in Y-o-Y growth due to postponed brain surgeries in hospitals and ambulatory surgical centers during the COVID-19 outbreak.

Request For Custom Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=84872

Rise in Incidence and Prevalence of High Grade Gliomas to Drive Market

In terms of type, the global glioma treatment market has been divided into low-grade gliomas and high-grade gliomas. High-grade gliomas is anticipated to be a highly lucrative segment in the near future due to the availability of more options for diagnosis and treatment of glioma tumor of this grade. High-grade gliomas are highly severe tumors and largely occur in children and adults. Various factors such as frequent radiation therapies, improper surgeries of the brain, and multiple therapies are expected to drive the market. Manufacturers are emphasizing on the use of innovative technologies, which is projected to fuel the segment in the near future. For instance, ASCO 2022 would get fresh clinical data on the usage of Kiyatec’s ex vivo 3D cell culture technique for high-grade glioma. Furthermore, rise in prevalence and incidence of high-grade gliomas is driving the market. High-grade glioma is one of the frequently diagnosed primary brain tumors. According to the National Library of Medicine, the incidence rate of high-grade glioma is about 5.8 males and 4.1 females per 100,000 people per year.

Surgery, the First Step in Treatment of Most Gliomas

Based on treatment, the surgery segment dominated the global glioma treatment market in 2021. This trend is projected to continue during the forecast period. Surgery to remove as many tumors as possible is usually the first step in treating most gliomas. In some cases, gliomas are small and can be easily removed from the surrounding healthy brain tissue, allowing for complete surgical removal. Moreover, presence of reimbursement policies that encourage healthcare providers to maintain quality infrastructure is expected to boost the surgery segment. Thus, increase in success rate of surgeries and reimbursement policies is expected to drive the surgery segment. Additionally, rise in number of surgical procedures for the treatment of glioma in growing economies, including China and India, is boosting the segment. Governments of China and India have increased their healthcare spend, which in turn is augmenting the admission of patients in hospitals.

Make an Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=84872

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update – https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Websitehttps://www.transparencymarketresearch.com
Bloghttps://tmrblog.com
Email: [email protected]

Related Posts

Leave a Comment